Clinical Trial Update: Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating XmAb18087 with or without pembrolizumab in advanced Merkel cell carcinoma and extensive-stage small cell lung cancer, terminated with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• XmAb18087 ( XmAb18087 )

Snippet

Sponsor: Xencor, Inc. | Conditions: Merkel Cell Carcinoma, Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-04-20